补心气口服液联合尼可地尔治疗冠心病心绞痛的临床研究

Clinical study on Buxinqi Oral Liquid combined with nicorandil in treatment of angina pectoris of coronary heart disease

目的探讨补心气口服液联合尼可地尔治疗冠心病心绞痛的临床疗效。方法选取2017年6月—2018年6月在邯郸市第二医院治疗的冠心病心绞痛患者94例,根据住院号分为对照组(47例)和治疗组(47例)。对照组患者口服尼可地尔片,10 mg/次,3次/d;治疗组在对照组基础上口服补心气口服液,10 mL/次,3次/d。两组患者均治疗3个月。观察两组患者临床疗效,同时比较治疗前后两组患者心电图改善情况、心绞痛发作次数和持续时间及血清学指标。结果治疗后,对照组患者临床和心电图有效率分别为80.85%和82.98%,均分别显著低于治疗组的95.74%和97.87%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者心绞痛发作次数、持续时间较治疗前均显著降低(P<0.05),且治疗组心绞痛发作次数和持续时间比对照组降低更明显(P<0.05)。治疗后,两组血清白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、基质金属蛋白酶-9(MMP-9)、髓过氧化物酶(MPO)和肌钙蛋白(CTnI)水平均显著降低(P<0.05),且治疗后治疗组上述血清学指标水平明显低于对照组(P<0.05)。结论补心气口服液联合尼可地尔治疗冠心病心绞痛能够明显改善患者心绞痛症状,降低机体炎症反应,降低心肌损害,具有一定的临床应用价值。

Objective To investigate the clinical efficacy of Buxinqi Oral Liquid combined with nicorandil in treatment of angina pectoris of coronary heart disease. Methods Patients(94 cases) with angina pectoris of coronary heart disease in Handan Second Hospital from June 2017 to June 2018 were divided into control(41 cases) and treatment(41 cases) groups based on admission number.Patients in the control group were po administered with Nicorandil Ttablets, 10 mg/time, three times daily. Patients in the treatment group were po administered with Buxinqi Oral Liquid on the basis of the control group, 10 mL/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, and the improvement of ECG, the frequency and duration of angina pectoris, the serological indexes in two groups before and after treatment were compared. Results After treatment,the clinical efficacy and ECG efficacy in the control group were 80.85% and 82.98%, which were significantly lower than 95.74% and97.87% in the treatment group, respectively, and there were differences between two groups(P < 0.05). After treatment, the frequency and duration of angina pectoris in two groups was significantly decreased(P < 0.05), and which in the treatment group was significantly lower than that in the control group(P < 0.05). After treatment, the serum IL-6, CTnI, TNF-α, MPO and MMP-9 levels in two groups were significantly decreased(P < 0.05), and these serological indexes levels in the treatment group were significantly lower than those in the control group(P < 0.05). Conclusion Buxinqi Oral Liquid combined with nicorandil in treatment of angina pectoris of coronary heart disease can significantly improve angina pectoris symptoms, reduce inflammation response and myocardial damage, which has a certain clinical application value.